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Abstract | An expert panel was convened in October 2013 by the International Scientific Association for 
Probiotics and Prebiotics (ISAPP) to discuss the field of probiotics. It is now 13 years since the definition 
of probiotics and 12 years after guidelines were published for regulators, scientists and industry by the Food 
and Agriculture Organization of the United Nations and the WHO (FAO/WHO). The FAO/WHO definition of 
a probiotic—“live microorganisms which when administered in adequate amounts confer a health benefit 
on the host”—was reinforced as relevant and sufficiently accommodating for current and anticipated 
applications. However, inconsistencies between the FAO/WHO Expert Consultation Report and the FAO/WHO 
Guidelines were clarified to take into account advances in science and applications. A more precise use of 
the term ‘probiotic’ will be useful to guide clinicians and consumers in differentiating the diverse products 
on the market. This document represents the conclusions of the ISAPP consensus meeting on the appropriate 
use and scope of the term probiotic.
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Introduction
In 2001, an Expert Consultation of international sci­
entists working on behalf of the Food and Agriculture 
Organization of the United Nations (FAO) and the WHO 
debated the emerging field of probiotics. One output was 
a reworking of the definition of probiotics to the follow­
ing: “live microorganisms which when administered in 
adequate amounts confer a health beneﬁt on the host”.1 
Since then, this definition has become the most widely 
adopted and accepted version worldwide. In 2002, an 
FAO/WHO Working Group produced guidelines to 
assist with interpretation of the original document.2 Since 
the Expert Consultation report, PubMed has indexed 
>8,000 additional research articles that use the term 
probiotic. The scientific and clinical evidence have pro­
gressed rapidly, as has the development of a number of 
robust probiotic products. Unfortunately, misuse of the 
term probiotic has also become a major issue, with many 
products exploiting the term without meeting the requi­
site criteria. At the same time, probiotic products have 
received the legitimate attention of regulatory authorities 
with an interest in protecting consumers from misleading 
claims. Now, it is timely to revisit the concept of what 
can be defined as a probiotic, consider appropriate 
d efinitions and provide useful guidance for stakeholders.
The International Scientific Association for Pro­
biotics and Prebiotics (ISAPP) organized a meeting of 
clinical and scientific experts on probiotics (with special­
ties in gastroenterology, paediatrics, family medicine, 
gut microbiota, microbiology of probiotic bacteria, 
microbial genetics, immunology and food science) held 
on 23 October 2013 to re­examine the concept of pro­
biotics. Participants included members of the original 
FAO/WHO Expert Panel, members of the FAO/WHO 
Working Group and other internationally recognized 
experts. Participants in the meeting jointly considered 
key questions and generated and approved the outcomes 
hereby summarized.
We hope that this Consensus Statement will provide all 
probiotic stakeholders, including consumers, research­
ers, health­care professionals, industry and legislators, 
with clearer guidelines for defining and using pro biotics, 
which we believe to be potentially important inter­
ventions for improved health and wellbeing. Throughout 
this paper, we use the term ‘probiotic framework’ to refer 
to all aspects of the probiotic field, including: scientific 
investigation and clinical research; regulatory involve­
ment in safety, health benefit claims and research; indus­
try activities including production, marketing, product 
claims and sales; and communication with the consumer. 
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Moreover, we propose a set of benchmark standards for 
the differentiation of probiotic products based upon 
levels of s cientific evidence. Panel recommendations are 
listed in Box 1.
Methods
This panel was conceived by the board of directors of 
ISAPP. ISAPP is an international nonprofit collabora­
tion of scientists dedicated to advancing scientific excel­
lence in probiotics and prebiotics. ISAPP’s activities are 
determined by the board of directors, comprising global 
academic scientists. Through its Industry Advisory 
Committee, ISAPP incorporates industry scientists in its 
activities and raises funds. ISAPP strives to be an objective, 
science­based voice for the probiotic and prebiotic fields.
To prepare for the panel, experts were selected from 
across a range of relevant disciplines, including current 
board members as well as external experts. Panellists 
developed a discussion outline and target questions. 
Sev eral panellists (C.H., B.P., G.R., F.G., M.E.S. and 
L.M.) delivered brief presentations that addressed the 
background and core issues involved for each question. 
Discussion ensued for each issue until a unanimous con­
sensus was achieved. After the meeting, indi vidual panel­
lists wrote sections of the summary, which were compiled 
into a draft report. This document was c irculated and 
agreed before submission.
Revisiting the term ‘probiotic’
‘Probiotic’ is a useful and accepted term. The FAO/
WHO definition has been widely adopted and has 
proven valuable to researchers, regulators and consum­
ers. Organizations and agencies such as Codex (which 
comes under the FAO/WHO umbrella), Health Canada,3 
the World Gastroenterology Organisation,4 the European 
Food Safety Authority (EFSA) and the Institute of Food 
Technologists5 use the FAO/WHO definition when 
referring to probiotics. The panel noted, however, that a 
more grammatically correct definition would be worded 
as, “live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” 
and supports use of this wording going forward. This 
definition is inclusive of a broad range of microbes and 
applications, whilst capturing the essence of probiotics 
(microbial, viable and beneficial to health). The definition 
differentiates live microbes used as processing aids or 
sources of useful compounds from those that are admin­
istered primarily for their health benefits.6 The distinction 
between commensal microorganisms and probiotics is 
also inferred from this definition. Although commensals 
in the gut are often the source of probiotic strains, until 
these strains are isolated, characterized and a credible 
case presented for their health effects, they cannot be 
called ‘probiotics’. In the 13 years that have passed since 
the definition was proposed, numerous lines of research 
have challenged the limits of the probiotic concept, from 
live cultures present in fermented foods to faecal micro­
biota transplants (FMT). The term has also been clearly 
misused, for example, on products such as mattresses, 
shampoos, disinfectants and aftershave, for which main­
tenance of viability and efficacy of the microbes used 
are not established. Use of the term probiotic has been 
restricted in some countries of the European Union 
because it is deemed misleading to consumers in the 
absence of approved health claims.7 It is now evident 
that different interpretations of the term probiotic are 
creating notable concerns for major stakeholders with 
respect to the translation of a large body of research on 
probiotics to probiotic­containing foods that can benefit 
consumers. The objectives of the different stakeholders 
in the pro biotic field are described in Figure 1; notably, all 
the stakeholders’ objectives are compatible. Importantly, 
all parties involved in the probiotic field must work 
toward a common goal so that society benefits from 
the scientific advances in the field of probiotic research. 
These concerns motivated the ISAPP to convene a panel 
of experts to address the following relevant questions with 
respect to defining the term probiotic.
Q Are there core benefits that can be ascribed to the general category of probiotics, and, if so, 
should the probiotic classification include live microbes 
identified to the species level, which can be reasonably 
expected to impart general benefits?
Probiotic benefits
On the basis of the currently available literature, which 
includes well­designed clinical trials, systematic reviews 
and meta­analyses, the consensus panel concurred 
that certain effects can be ascribed to probiotics as 
a general class. In this context, we refer to strains of a 
number of well­studied microbial species delivered at 
a functional dose for use as foods or supplements in 
the general population—not strains used as drugs. This 
opinion aligns with regulatory approaches in Canada 
and Italy. Health Canada has accepted the following 
bac terial species, when delivered in food at a level of 
1 × 109 colony forming units (CFU) per serving, as pro­
biotics for which nonstrain­specific claims might be 
made: Bifidobacterium (adolescentis, animalis, bifidum, 
breve and longum) and Lactobacillus (acidophilus, casei, 
fermentum, gasseri, johnsonii, paracasei, plantarum, 
rhamnosus and salivarius).3 This list represents a core 
group of well­studied species likely to impart some 
general benefits. Acceptable claims on Canadian foods 
Box 1 | Consensus panel recommendations for the scope of probiotics
 ■ Retain the FAO/WHO definition1 for probiotics, with a minor grammatical 
correction as “live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host”; inconsistences between the 
Expert Consultation1 and the FAO/WHO Guidelines2 were clarified
 ■ Include in the framework for definition of probiotics microbial species that have 
been shown in properly controlled studies to confer benefits to health
 ■ Any specific claim beyond “contains probiotics” must be further substantiated
 ■ Keep live cultures, traditionally associated with fermented foods and for which 
there is no evidence of a health benefit, outside the probiotic framework
 ■ Keep undefined, faecal microbiota transplants outside the probiotic framework
 ■ New commensals and consortia comprising defined strains from human 
samples, with adequate evidence of safety and efficacy, are ‘probiotics’
Abbreviation: FAO, Food and Agriculture Organization of the United Nations.
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for these probiotics are based on their contribution to 
a healthy gut microbiota. Similarly, nutrition recom­
mendations in some European Union countries suggest 
the consumption of specific species for nutrition and 
health benefits.8 For more than 30 years, Italy has had 
a tradition of using beneficial bacteria, administered as 
food supplements or food ingredients, to help manage 
the intestinal microbiota. The Italian Ministry of Health 
has regulated the use of probiotic bacteria in the food 
sector over the past 12 years and, in 2013, confirmed the 
use of the word probiotic for food and food supplements 
under certain conditions, including a minimum number 
of viable cells (1 × 109 CFU) administered per day, a full 
genetic character ization of the probiotic strain and a 
d emonstratable history of safe use in the Italian market.9
Thus, Canada and Italy consider the general benefit of 
supporting a healthy gut microbiota to be a core benefit 
of probiotics. The consensus panel agrees with this 
approach, while acknowledging that the current state 
of science does not allow the clear definition of a 
healthy gut microbiota based on microbial composi­
tion.10 Nevertheless, the general benefit of probiotics 
on gut microbiota derives from creating a more favourable 
gut environment, through mechanisms shared by most 
probiotics. The panel further considered two common 
general benefits often associated with p robiotics: support­
ing a healthy digestive tract and a healthy immune system. 
The panel concluded that the general benefit of support­
ing a healthy digestive tract was re inforced by evidence 
gathered on a large number of different pro biotic strains 
representing commonly studied species. This conclu­
sion was based on a body of available research, including 
high­quality meta­analyses, on a diversity of clinical end 
points (such as infectious diarrhoea, antibiotic­associate d 
diarrhoea, gut transit, IBS, abdominal pain and bloat­
ing, ulcerative colitis and necrotizing enterocolitis11–15), 
as well as potential mechanistic actions suggesting that 
most strains of these species can be expected to have 
such ‘generic’ or ‘core’ effects on gut physiology and 
health. The core benefit of support ing a healthy immune 
system was considered by the panel to be widely acknowl­
edged, but probably more strain­specific.16,17 The diverse 
meaning of ‘support ing a healthy immune system’, which 
ranges from preventing allergic disease to downregulation 
of inflammation to the enhancement of anti­infection 
activities was considered to be too broad to be consid­
ered a core benefit. Other benefits such as supporting the 
health of the reproductive tract, oral cavity, lungs, skin 
and gut–brain axis are promising, but evidence has not yet 
been linked to a broad enough cross­section of probiotics 
to consider these effects to be probably shared across the 
whole class of probiotics.
Underlying mechanisms
The panel considered the current understanding of the 
mechanisms underlying probiotic effects. Figure 2 con­
siders, in a general sense, the distribution of mechanisms 
among probiotic strains. Although specific attributions 
can be debated, the key point is that some mechanisms 
are widespread among a diversity of strains whereas others 
are less so. Widespread mechanisms can be associ ated 
with effects that are observed across taxonomic groups, 
such as inhibition of potential pathogens or the produc­
tion of useful metabolites or enzymes.18,19 Other effects at 
the intestinal or extraintestinal level, including immune 
effects, are more likely to be strain­specific20 and claims 
of such benefit can only be made for strains or species in 
which the mechanistic basis has been demonstrated.21,22 
In many cases, a given probiotic might exert several health­
promoting effects. Although multiple mechanisms are 
often represented in a single strain, no individual probiotic 
would be expected to have all the effects listed in Figure 2.
Core benefits
The panel is convinced that sufficient evidence has 
accumulated to support the concept of ‘core’ benefits of 
certain probiotics; it is reasonable to expect that evidence 
gained from a defined class of live microbes might be 
appropriate for certain, but not all, health outcomes. This 
stance is in contrast to a prevailing perspective that every 
probiotic strain is different and probably elicits a differ­
ent outcome in the host. We conclude that this more­
nuanced understanding of probiotics is justified based 
on accumulated evidence from the hundreds of human 
studies and dozens of positive meta­analyses available 
today. It seems remarkable that probiotic strains selected 
decades ago for use in commercial probiotic products 
(in which strain robustness, growth and stability would 
have been the central criteria) have proven to be effec­
tive in conferring a health benefit in multiple trials with 
various end points. This finding supports the concept 
that there are common health benefits to be derived from 
consuming (or delivering) at an adequate dose any safe 
strain of a species that is already known to include an 
effective probiotic. For example, if the hypothesis under 
investigation was “safe bacterial cultures administered 
in high doses will have a beneficial outcome in gastro­
intestinal diseases”, then the appropriate methodology 
would be to select a wide range of individual bacterial 
Scientists…
…want to generate
high-quality science
that has a positive
impact on society
Industry…
…want high-quality,
protable products,
with validated and
understandable claims
Regulators…
…want to protect
consumers from
misinformation
Consumers…
…want reliable
information to make
informed decisions
Probiotics
Figure 1 | Objectives of stakeholders in the probiotic field. 
These objectives are compatible, so there is no apparent 
reason for obstruction of probiotic product development 
and marketing. Importantly, all stakeholders must work 
together performing their respective duties so that 
society benefits from the scientific advances in the field 
of probiotic research.
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strains or strain mixes, and test them in multiple set­
tings in diverse patient groups. The outcome of all of the 
individual trials would then be analysed collectively. This 
approach is essentially what has been done in numerous 
meta­analyses conducted on multiple probiotic strains 
that have been used in human trials.
One such meta­analysis was performed by Ritchie and 
Romanuk,11 which included a broad range of probiotic 
strains; null studies were also part of the analysis. In 
their meta­analysis containing 74 studies, 84 trials and 
10,351 patients, the authors concluded that, in general, 
probiotics are beneficial in the treatment and preven­
tion of gastrointestinal diseases. This approach of com­
bining probiotic strains of various genera and species 
into one functional ‘class’ has already been accepted by 
EFSA for yogurt cultures, as evidenced by an approved 
claim for Lactobacillus delbrueckii subsp. bulgaricus and 
Streptococcus salivarius subsp. thermophilus in aiding 
lactose digestion.23 The EFSA, in this instance, accepted 
characterization at the species—not strain—level because 
the mechanism of action is clearly understood as being 
microbial production of β­galactosidase, which aids 
lactose digestion in the gut. However, the claimant does 
not have to demonstrate that every strain of L. delbru‑
ueckii subsp. bulgaricus or S. salivarius subsp. thermo‑
philus produces sufficient lactase to support the claim, 
and so the benefit is ascribed to this class of microbe. 
Similarly, whereby a core benefit could be associated with 
a particular structure or activity, it would be reasonable 
to use data accumulated for any strain exhibiting that 
property as support for a health claim. It would also 
seem equitable to allow the use of the term ‘probiotic’ 
for a member of a species for which systematic reviews 
or meta­analyses indicate a general health benefit, par­
ticularly (or perhaps only) if a specific health claim was 
not being communicated on the product.
Q Should the probiotic framework include traditional fermented foods containing live microbes?
The panel acknowledged that evidence supports the 
beneficial relationship between some foods containing 
live microbes, especially fermented dairy products, and 
reduced risk of certain diseases. For example, fermented 
dairy products have been associated with reduced risk of 
type 2 diabetes or improved markers of glucose homeo­
stasis,24–26 less weight gain over time in a prospective study 
of >120,000 adults27 and reduced risk of overall mortal­
ity.28 An observational study of >6,500 indivi duals found 
that yogurt consumers had reduced levels of circulat­
ing triglycerides and glucose, as well as reduced systolic 
blood pressure and insulin resistance, compared with 
non consumers.29 Consumption of foods containing live 
microbes might therefore be a beneficial dietary recom­
mendation. However, in the panel’s judgement, it is not 
always possible to clearly distinguish the contribution of 
the live microbes from that of the food matrix in such 
studies. Furthermore, potentially beneficial microbes 
might often represent a diverse community that is not 
well­defined in terms of strain composition and stability. 
As a result, the live microbes in such foods fall short of the 
criteria needed to be considered ‘probiotics’. It was recom­
mended that such foods are best described as ‘containing 
live and active cultures’, but should not be called probiotic.
Q Should the probiotic framework include well‑defined beneficial commensal microbes?
Research has suggested that certain individual constituents 
of the human microbiota might represent novel candidates 
for new probiotics. Metagenomic studies provide a profile 
of the microbial communities in the human gut and reveal 
an association between low microbial diversity and several 
disease states, including IBD, metabolic disorders and 
IBS.30–36 Even if a cause–effect relationship between low 
microbial richness and disease has not been established, 
it is known that exposure to antibiotics early in life is a 
risk factor for the development of IBD37 or obesity,38 sug­
gesting that depletion of some critical commensals might 
have health consequences later in life. These observations, 
among others, support the hypothesis that the increasingly 
vulnerable human microbiota and specifically defective 
colonization by ‘old friends’ play a part in the aetiology of a 
number of disorders of modern society.39,40 Hypothetically, 
replacement of the missing commensal microbes with 
individual strains or defined strain mixes could help in 
the prevention and treatment of such disorders.
Metagenomic studies of the human microbiome have 
identified a number of genera and species that are associ­
ated with a robust gut microbiota composition, and 
experimental work in animal models of disease has pro­
vided evidence that some of them might be useful tools 
to mitigate intestinal inflammation,41 induce immune 
regulation,42 or enhance intestinal barrier function.43 
These microbes include Akkermansia muciniphila44 
and Faecalibacterium prausnitzii 45 together with other 
butyrate­producing bacteria such as Roseburia spp.46 and 
Widespread
Among studied probiotics
■ Colonization resistance
■ Acid and SCFA production
■ Regulation of intestinal transit
■ Normalization of perturbed microbiota
■ Increased turnover of enterocytes
■ Competitive exclusion of pathogens
Frequent
Species-level effects
■ Vitamin synthesis
■ Direct antagonism
■ Gut barrier reinforcement
■ Bile salt metabolism
■ Enzymatic activity
■ Neutralization of carcinogens
Rare
Strain-specic effects
■ Neurological effects
■ Immunological effects
■ Endocrinological effects
■ Production of specic bioactives
Figure 2 | Possible distribution of mechanisms among probiotics. Some 
mechanisms might be widespread among commonly studied probiotic 
genera; others might be frequently observed among most strains of a probiotic 
species; others may be rare and present in only a few strains of a given species. 
Evidence is accumulating on a cross-section of probiotic strains that suggest 
some generalizations can be made beyond strain-specific effects. Abbreviation: 
SCFA, short-chain fatty acid.
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Eubacterium hallii.47 Whether these microbes can be used 
in foods, dietary supplements, medical foods, medical 
devices or drugs will depend on demonstration of safety 
and efficacy for these uses and within regulatory frame­
works. The panel considered that such microbes clearly 
fall under the term probiotic, as long as suitable safety 
assessments are conducted.6 For these new probiotics, 
which might comprise little­studied species, it would seem 
advisable to proceed on a strain­by­strain basis until such 
time that there is sufficient information and  mechanistic 
understanding for extrapolation to the species level.
Q Should the probiotic framework include undefined consortia of commensals derived from sampling 
human body sites?
The panel acknowledged the increased use of undefined 
mixtures of microbes derived from human samples to 
treat gastrointestinal diseases through FMT.48 To date, 
most clinical experience has focused on the use of FMT 
in patients with relapsing diarrhoea due to Clostridium dif‑
ficile infection, in which the procedure resolves recurrence 
in ~90% of cases.49 Interest also exists in the therapeutic 
potential of FMT for IBD, IBS and some extraintestinal 
conditions such as metabolic and autoimmune diseases.48 
The safety (especially in the long term) of such pro cedures 
remains to be established.50 Donor FMT mixtures can 
comprise a number of unknown taxa, including bacteria, 
yeasts, parasites and viruses, and it is not known which 
microbes are responsible for the beneficial effect, and 
which might pose a risk through transfer of antibiotic 
resistance, production of genotoxic metabolites or intes­
tinal translocation. In addition, FMT cannot be standard­
ized, even with the same donor, due to inter­individual 
and intra­individual variability of the gut microbiota.51 
Nevertheless, regulatory authorities in the USA, which 
initially banned all clinical use of FMT except under an 
investigational new drug application, reversed course and 
now allow clinical use for treatment of C. difficile disease.52
The lack of identification of the microbes being used 
from a wide range of donors motivated the panel to exclude 
FMT from the probiotic framework. In a similar manner, 
undefined collections of microbes from other human 
body sites are not considered pro biotics. However, the 
panel determined that preparations of defined mixes of 
microbes such as ‘RePoop’,53 in an approach coined ‘micro­
bial eco systems therapeutics’ by Petrof and colleagues,54 did 
meet the criteria of a probiotic, as long as the microbial 
preparation s comprise well­defined microbial components.
Q Should the FAO/WHO definition and guidelines continue to be endorsed?
Thus far we have described examples of how different 
microbes meet the FAO/WHO definition of a probiotic. 
The panel determined that this definition remains rel­
evant and useful for scientists and regulators to define 
the broad category of probiotics. Furthermore, we con­
sidered that the FAO/WHO Guidelines were also rel­
evant, with one modification. These Guidelines state: 
“Use and adoption of the guidelines in this report should 
be a prerequisite for calling a bacterial strain probiotic”. 
The panel considered that due to the accumulated evi­
dence, general benefits can be reasonably associated 
with well­researched probiotic species, to the extent that 
even if randomized controlled trials (RCTs) are not con­
ducted on specific strains, they might still be considered 
as ‘probiotics’. In addition, the section of the Guidelines 
addressing genetic characterization of probiotics should 
be updated to include the use of genomic sequencing as 
part of a thorough safety assessment.
Other inconsistencies between documents were noted. 
The purpose of the Expert Consultation and Working 
Group, convened by the FAO/WHO in 20011 and 2002,2 
respectively, was to establish guidelines for assessing the 
efficacy of probiotics delivered as food. However, numer­
ous examples of probiotic delivery that extend beyond food 
applications appear in these documents. For example, the 
probiotic definition adopted by the Expert Consultation 
clearly was not limited to pro biotic foods, and indeed 
included non­oral applications. The word ‘administered’ 
was deliberately chosen rather than ‘consumed’ and no 
limits were placed on the type of health effects or target 
populations in the definition, thereby allowing many 
applications to be feasible. Most of the evidence listed 
for probiotic beneficial effects dealt with patho logical 
conditions, which correctly belong in the realm of drug 
applications as currently differentiated by most regula­
tory agencies. Another inconsistency between the two 
documents is that the Expert Consultation1 stated that the 
ability to remain viable at the target site should be verified 
for each potential strain. This point was not included in the 
Guidelines.2 The Expert Consultation further states that 
“…traditional starters are not to be considered probiotics 
since they lack the ability to proliferate in the intestine”. 
However, the 2002 Guidelines recognized probiotic status 
for trad itional yogurt cultures (S. salivarius subsp. thermo‑
philus and L. delbrueckii subsp. bulgaricus) owing to their 
ability to improve tolerance to lactose in mal digesters. 
The beneficial effects of these cultures have since been 
endorsed by the EFSA.23 Certainly, other health benefits 
that do not require a strain to proliferate in the intestine are 
c onceivable and are within the scope of probiotics.
As would be expected given the rapidity of scientific 
breakthroughs, the research regarding the mechanisms 
and health effects of probiotics extend much beyond what 
was included in the 2001 Expert Consultation.1 Never­
theless, the definition remains relevant, and the Guidelines 
document still provides a useful approach to validating a 
probiotic strain.
Q What is an appropriate level of evidence for determining a health benefit for probiotics?
To determine whether an association exists between a 
substance (such as a probiotic) and a desired outcome 
(such as maintaining a healthy digestive system), it is 
important to examine the following criteria: temporal 
relationship; strength of relationship; dose response; rep­
lication of findings; biological plausibility; consider ation 
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of alternative explanations; cessation of exposure; speci­
ficity of the association; and consistency with other 
knowledge.55,56 Subtle discrepancies exist among different 
epidemiological authorities but these criteria (based on 
the Bradford Hill Criteria) are important factors for deter­
mining a causal relationship. Appropriately powered, 
well­designed RCTs, preferably assessed through the sys­
tematic review and meta­analysis process, provide the 
evidence to draw conclusions on causality. However, such 
studies might not be available for determining strength of 
evidence to substantiate health­benefit claims for dietary 
(nutritional) s upplements or foods.
The panel also believes that probiotic foods or supple­
ments should not be held to a higher standard of evidence 
than other foods or supplements. No probiotic claims 
have been judged sufficiently substantiated for foods in 
the European Union. Evidence that vitamin C reduced 
tiredness and fatigue, contributed to normal energy­
yieldin g metabolism and maintained the normal function 
of the immune system was deemed sufficient,57 yet there 
are no robust RCTs in healthy individuals supporting these 
benefits—the importance of dietary vitamin C is based 
on malnourished patients who have developed scurvy.58–61 
Many other supplements are also recommended by doc­
tors for uses not supported by RCTs. For example, for bone 
health, many primary­care p hysicians recommend supple­
mentation with calcium and vitamin D, yet limited RCT 
evidence exists to support this recommendation. Indeed, 
a Cochrane review found that evidence does not support 
vitamin D supplementation to improve bone density in 
healthy children.62
Health effects of probiotics are supported by many well­
conducted RCTs and high­quality systematic reviews and 
meta­analyses.14,63–66 That the totality of evidence must be 
Table 1 | Categories of live microorganisms for human use as defined by the expert panel
Description Claim Criteria* Minimum level of evidence 
required to make claim
Comments
Not probiotic
Live or active 
cultures
“Contains live and 
active cultures”
Any food fermentation microbe(s)
Proof of viability at a minimum level 
reflective of typical levels seen in 
fermented foods, suggested to be 
1 × 109 CFU per serving73
No product-specific efficacy 
studies needed
The terms ‘live’ or ‘active’ do not 
imply probiotic activity
Fermented foods containing live 
cultures might also qualify as a 
‘probiotic’ if they meet the criteria 
for that category (e.g. evidence that 
yogurt can improve lactose digestion 
in lactose maldigesters would 
qualify it as a ‘probiotic’74,75)
Probiotic
Probiotic 
in food or 
supplement 
without 
health claim
“Contains probiotics” A member(s) of a safe76,77 species, 
which is supported by sufficient 
evidence of a general beneficial 
effect in humans OR a safe 
microbe(s) with a property (e.g. 
a structure, activity or end product) 
for which there is sufficient 
evidence for a general beneficial 
effect in humans
Proof of viability at the 
appropriate level used in 
supporting human studies73
Well-conducted human studies 
(e.g. these could involve RCT(s), 
observational studies, systematic 
reviews or meta-analyses 
supporting the observed general 
beneficial effect for the taxonomical 
category concerned)
The evidence does not have to be 
generated for the specific strain 
included in the product
Extrapolation of evidence must be 
based on reasonable expectations 
that the strain(s) incorporated in the 
product would have similar general 
beneficial effects in humans
This evidence could be based 
on taxonomical or functional 
comparisons
Probiotic 
in food or 
supplement 
with a 
specific 
health claim
Specific health claim, 
such as “helps to 
reinforce the body’s 
natural defences in 
children” or “helps 
reduce the risk of 
antibiotic-associated 
diarrhoea”
Defined probiotic strain(s)
Proof of delivery of viable strain(s) 
at efficacious dose at end of 
shelf-life73
Convincing evidence needed for 
specific strain(s) or strain combination 
in the specified health indication
Such evidence includes well-
conducted studies in humans, 
including: positive meta-analyses 
on specific strain(s) or strain 
combinations, as per principles 
outlined by Cochrane,78 PASSCLAIM,79 
or GRADE;80 well-conducted RCT(s) 
OR strong evidence from large 
observational studies81
Well-designed observational 
studies are useful to detect the 
effect of foods on health in ‘real 
life’, that is, outside the controlled 
environment of an RCT (e.g. data 
on health benefits by dietary fibre 
are mostly observational)
Sample sizes must be large enough 
to manage confounding factors
Probiotic 
drug
Specific indication for 
treatment or prevention 
of disease, such as 
“useful for the 
prevention of relapse 
of ulcerative colitis”
A defined strain(s) of live microbe
Proof of delivery of viable  
probiotic at efficacious dose  
at end of shelf-life
Risk–benefit assessment 
justifies use
Appropriate trials to meet regulatory 
standards for drugs
What constitutes a drug claim varies 
among countries
*Unless otherwise indicated, all criteria indicated must be met. Abbreviations: CFU, colony forming unit; GRADE, Grades of Recommendation Assessment, Development and Evaluation; 
PASSCLAIM, Process for the Assessment of Scientific Support for Claims on Food; RCT, randomized controlled trial.
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considered when evaluating evidence for health benefits 
is widely accepted. The panel urges a consistent approach 
be taken to clinical, food and dietary recommendations 
by health­care professionals and regulators.
Implications of the recommendations
The marketplace has many products carrying the label 
‘probiotic’, but too often they do not meet minimum 
criteria, such as defined contents, appropriate viable 
count at end of shelf­life and suitable evidence for 
health benefit. The panel recommends that the term pro­
biotic be used only on products that deliver live micro­
organisms with a suitable viable count of well­defined 
strains with a reasonable expectation of delivering 
b enefits for the wellbeing of the host (Table 1).
In addition, there is a need for clear communica­
tion to consumers and health­care providers on how 
to differentiate probiotic products. Unfortunately, this 
goal is difficult to achieve because of regulatory agency 
restrictions on what can be communicated on product 
labels. Restricting use of the term probiotic on foods, 
as has occurred in some countries in the European 
Union, is unwarranted when minimum criteria are met. 
A product­ labelling approach that communicates the 
information known about the probiotic being sold would 
be more useful for consumers and health­care providers.
This panel, or any other panel of experts, cannot force 
change and, ultimately, the marketplace and regulators will 
decide which probiotics are made available for consumers. 
However, as supporters of the importance of translating 
the benefits of rigorous scientific and medical research, 
we reiterate that studies have shown, and continue to 
show, that certain types of microorganisms are beneficial 
to human health, and we suggest that limiting consumer 
access to this information has negative implications for the 
health of adults and children around the world.
Conclusions
The panel believes its recommendations are important 
for several key reasons. Research advances over the past 
12 years warrant discussion about the relevance of the 
probiotic concept.67–69 The panel found that the defini­
tion of a probiotic advanced by the FAO/WHO in 2001 is 
sufficiently broad to enable a wide range of products to be 
developed, and sufficiently narrow to impose some core 
requirements (Table 1). The development of metabolic 
by­products, dead microorganisms, or other microbial­
based, nonviable products has potential; however, these 
do not fall under the probiotic construct. Figure 3 rep­
resents an overall framework for use of the term ‘pro­
biotic,’ encompassing diverse end uses. Substantial 
confusion exists in the regulation of probiotics, in many 
cases because regulators are attempting to apply schemes 
to probiotic foods and supplements that were initially 
designed to facilitate pharmaceutical development. We 
concur with a report published in 201370 that changes are 
needed to how probiotics are handled by regulators in 
jurisdictions such as the USA and Europe. However, we 
disagree strongly with the regulatory action by the FDA 
in the USA to require investigational new drug applica­
tions for all functional end points for probiotic foods 
and for most dietary supplements.71 This action will 
severely hinder the conduct and increase the cost of safe, 
much­needed research on probiotics, through unneces­
sary bureaucratic requirements that are difficult, if not 
impossible, to meet for products not manufactured using 
pharmaceutical standards. The drug approach to research 
can add to the cost and delay needed efficacy studies 
by requiring safety studies not considered necessary by 
Institutional Review Boards overseeing the research. 
The panel identifies a need to improve communication 
to the public and health­care professionals on the benefits 
of probiotics, which can be expected for the general popu­
lation. The panel also acknowledges that robust evidence 
must be provided for benefits tied to specific strains. This 
stance is similar to a category system originally proposed 
in 2012,67 but laid out clearly for all stakeholders.
The field of probiotics has advanced considerably in 
recent years, spurred by global progress in understanding 
the role of the human microbiota in health and disease 
and the need to define effective strategies to shape a 
healthier microbiota. Well­controlled intervention trials, 
systematic reviews and meta­analyses provide convinc­
ing evidence of the benefits of probiotics, including ones 
with valuable public health implications.68,72 Clarifying 
the proper scope and appropriate use of the term pro­
biotic is important so that all stakeholders in the probiotic 
field, as depicted in Figure 1, share an understanding of 
probiotics that is consistent with current research. This 
clarification will facilitate continued advances in probiotic 
research and will ensure probiotic benefits are properly 
communicated to consumers and patients.
Live cultures
Probiotic
Probiotic
foods
Probiotic
drugs
Probiotic
medical
foods
Probiotic
infant
formula
Dened
microbial
consortia
Non-oral
probiotics
Probiotic
animal
feed
Fermented foods
with undened
microbial content
Undened consortia,
including faecal
microbiota transplant
Probiotic
dietary
supplement
Not probiotic
Figure 3 | Overall framework for probiotic products. Evidence of a health benefit is required for a probiotic, at either a 
strain-specific or group level, depending on the nature of the benefit. Probiotics can have different means of administration, 
target host species (humans and animals), target populations, target sites (gut and beyond), efficacy end points and 
regulatory categories. All probiotics must be safe for their intended use. Dead microbes, microbial products, microbial 
components do not come under the probiotic classification.
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